ML26035A419
| ML26035A419 | |
| Person / Time | |
|---|---|
| Site: | SHINE Medical Technologies (CPMIF-001) |
| Issue date: | 02/04/2026 |
| From: | Bartelme J SHINE Technologies |
| To: | Office of Nuclear Reactor Regulation, Document Control Desk |
| Shared Package | |
| ML26035A418 | List: |
| References | |
| 2026-SMT-0010 | |
| Download: ML26035A419 (0) | |
Text
February 4, 2026 2026-SMT-0010 10 CFR 50.80 10 CFR 50.90 U.S. Nuclear Regulatory Commission ATTN: Document Control Desk Washington, D.C. 20555-0001
Subject:
Application for Order Approving Transfers of Construction Permit and Conforming Administrative Amendments - Expedited Review Requested SHINE Technologies, LLC Construction Permit No. CPMIF-001 NRC Docket No. 50-608 Pursuant to Section 184 of the Atomic Energy Act of 1954, as amended (AEA), and 10 CFR § 50.80, Illuminated Holdings, Inc. (Illuminated) and its wholly-owned subsidiary SHINE Technologies, LLC (SHINE Technologies) (together, Applicants) submit the enclosed application (Application) requesting the U.S. Nuclear Regulatory Commission (NRC) consent to the direct and indirect transfer of control of Construction Permit No. CPMIF-001 (the CP) for the SHINE Technologies medical isotope production facility held by SHINE Technologies.
Applicants also request that the NRC issue conforming administrative amendments described in the Application and amend the CP to reflect the transfers of control.
The Application and requested consent are necessitated by an advanced loan application with the U.S. Department of Energys (DOE) Office of Energy Dominance Financing to provide funds for the completion of construction of the medical isotope facility. To facilitate the loan application and DOE loan, Illuminated will create a new wholly owned subsidiary, SHINE Chrysalis, LLC (SHINE Chrysalis) to complete financing and construction of the medical isotope production facility. The direct transfer of control will occur when Illuminated transfers the CP and assets relied on for the medical isotope production facility and personnel with responsibility for construction and associated permitted activities from SHINE Technologies to SHINE Chrysalis. The indirect transfer of control will occur concurrently with the direct transfer of control as SHINE Chrysalis Holdings, LLC (Chrysalis Holdings), a direct subsidiary of Illuminated, becomes the direct parent company of SHINE Chrysalis. Following the transfers of control, SHINE Chrysalis will be an indirect subsidiary of Illuminated. provides a non-public (proprietary) version of the Application. Applicants respectfully request that the NRC withhold Enclosure 1 from public disclosure pursuant to 10 CFR
§ 2.390. Enclosure 2 provides an affidavit supporting the proprietary treatment of Applicants proprietary information pursuant to 10 CFR § 2.390. Upon removal of Enclosure 1, this letter is uncontrolled. Enclosure 3 provides a public (non-proprietary) version of the Application.
Pursuant to 10 CFR § 50.90, Applicants also request NRC approval of certain administrative amendments to conform the CP to reflect the proposed transfer. The proposed conforming amendment is essentially a name change; there are no changes to the facility or
U.S. Nuclear Regulatory Commission February 4, 2026 Page 2 qualifications of the CP holder. Enclosure 4 identifies the proposed changes to the CP. Enclosure 5 provides proposed clean pages for the amended CP.
Because of the timing of the anticipated DOE loan, Applicants request an expedited review of the Application. An expedited review of the Application is appropriate because the transfers will not affect the activities authorized by the CP. The transfers will not affect the organizational or operational structure described in the CP. More specifically, there are no anticipated changes in personnel, operating organizations, locations, facilities, equipment, quality assurance plan, or procedures associated with licensed activities that would require NRC approval. This expedited review request is consistent with the current executive direction to develop domestic industrial nuclear infrastructure and enable nuclear innovation.1 Applicants are prepared to work closely with the NRC Staff to facilitate the Application review.
Applicants therefore request the NRC issue an order granting its consent to the proposed transfers of control by March 31, 2026.
In summary, the proposed transfers will not be inimical to the common defense and security or result in any undue risk to public health and safety, and the transfers will be implemented consistent with the requirements of the AEA and NRC regulations.
If you have any questions, please contact me.
Sincerely, Jeff Bartelme Senior Director of Regulatory Affairs SHINE Technologies, LLC 3400 Innovation Court Janesville, WI 53546 (608) 210-1735 jeffbartelme@shinefusion.com
- Application for Order Approving Transfers of Construction Permit and Conforming Administrative Amendments (CPMIF-001) (Proprietary)
- Application for Withholding Proprietary Information Treatment Under 10 CFR
- Application for Order Approving Transfers of Construction Permit and Conforming Administrative Amendments (CPMIF-001) (Public) 1 See Executive Order 14302 of May 23, 2025, Reinvigorating the Nuclear Industrial Base, 90 Fed. Reg. 22,595 (May 29, 2025).
U.S. Nuclear Regulatory Commission February 4, 2026 Page 3
- Construction Permit No. CPMIF-001 (Changes)
- Construction Permit No. CPMIF-001 (Clean Pages)
- QA Program Description (Changes)
- QA Program Description (Clean) cc w/
Enclosures:
Mike Balazik (via email)
Project Manager U.S. Nuclear Regulatory Commission Jeremy Wachutka (via email)
Office of General Counsel U.S. Nuclear Regulatory Commission
U.S. Nuclear Regulatory Commission February 4, 2026 Page 4 Applicants also would appreciate the NRC adding the individuals on the attached list to the service list for correspondence related to the Application.
ADDITIONS TO SERVICE LIST Timothy P. Matthews Scott D. Clausen Morgan, Lewis & Bockius LLP 1111 Pennsylvania Ave., NW Washington, D.C. 20004 Telephone: (202) 739-3000 Email: timothy.matthews@morganlewis.com Email: scott.clausen@morganlewis.com